MedPath

Preoperative Oral Carbohydrate Loading Versus Fasting in Patients Undergoing Major Abdominal Surgery

Not Applicable
Recruiting
Conditions
Carbohydrate
Major Abdominal Surgery
Fasting
Registration Number
NCT06243367
Lead Sponsor
Tanta University
Brief Summary

The aim of this study is to compare the effect of preoperative carbohydrate load versus the fasting protocol in patients undergoing major abdominal operations.

Detailed Description

The surgical patients are influenced by many stressors during operation such as the prolonged fasting hours. Importantly, these stressors are iatrogenic and have been shown to disturb homeostasis with little benefit. Surgery itself, induces an endocrine and inflammatory stress response and contributes to postoperative insulin resistance (PIR) which increased also by Preoperative fasting.

Postoperative insulin resistance is a state of reduced insulin-mediated glucose uptake in skeletal muscles and adipose tissue, with an increased glucose release due to hepatic gluconeogenesis and hyperglycemia.

Strategies to reduce the postoperative stress response and postoperative insulin resistance include shortening the preoperative fasting time via preoperative carbohydrate oral drink administration (carbohydrate load). Preoperative fasting is the first step in postoperative insulin resistance development. The traditional fasting time of 6-8 h before elective surgery to prevent pulmonary aspiration usually extends up to 12 h in anesthetic practice. Overnight fasting is a physiological state of reduced insulin sensitivity due to the normal hormonal diurnal rhythm. If patients undergo surgery in the prolonged fasted state, insulin resistance may begin even before surgery.

A preoperative carbohydrate drink acts as a morning meal, may improve insulin sensitivity and propel the patient's metabolic state towards anabolism. The rationale of this study is to compare the differences between preoperative CHO loading and a conventional fasting protocol on the postoperative insulin resistance, Glasgow prognostic score (GPS), subjective patient well-being and surgical clinical outcome.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Age from 21 and 70 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status l & ll.
  • Scheduled for elective major abdominal surgery
Exclusion Criteria
  • Disseminated malignant disease.
  • Increased risk for gastric content aspiration.
  • Body Mass Index (BMI) below 20 or above 30 kg/m2.
  • Nutritional risk screening 2002 score above 3.
  • Emergency surgery, diabetic patients, immunomodulatory therapy.
  • Refusal of the patient.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The metabolic response5 days postoperatively

The patient was also subjected to further assessment by bioelectrical impedence analysis for measuring of the basal body muscle mass preoperatively and 5 days postoperatively.

Secondary Outcome Measures
NameTimeMethod
Postoperative discharge day27 days postoperatively

Postoperative discharge day will be recorded.

Time of independent ambulation27 days postoperatively

Time of independent ambulation will be recorded.

The postoperative inflammatory responseFirst day postoperative

Postoperative inflammatory response was assessed at 6 o'clock A.M on the day of surgery (T1, basal value), 6 h after surgery (T2), at 6 o'clock A.M on postoperative day 1 (T3) .

Complications24 hours postoperatively

Complications such as nausea and vomiting were assessed preoperatively and at intervals 4, 8, 12, and 24 hours postoperatively

Trial Locations

Locations (1)

Tanta University

🇪🇬

Tanta, El-Gharbia, Egypt

Tanta University
🇪🇬Tanta, El-Gharbia, Egypt
Eman M Abo-Omar, Master
Contact
00201090822808
emantaher6669@gmail.com
Sohair M Soliman, MD
Sub Investigator
Naglaa K Yousef, MD
Sub Investigator
Taysser M Abdalraheem, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.